ライフサイエンスコーパス: pulmonary capillary

1 ormal trafficking of neutrophils through the pulmonary capillaries.

2 es rapid sequestration of neutrophils within pulmonary capillaries.

3 d in the lungs immediately upon reaching the pulmonary capillaries.

4 apid sequestration of neutrophils within the pulmonary capillaries.

5 apid sequestration of neutrophils within the pulmonary capillaries 1 min after intravascular injectio

6 increased margination of neutrophils within pulmonary capillaries (39.7 +/- 9.4 vs. 4.6 +/- 1.1 neut

7 determined by electron microscopy imaging of pulmonary capillaries and (125)I-albumin transport from

8 mooth muscle cells, and endothelial cells of pulmonary capillaries and arteries.

9 PECAM-1 in neutrophil emigration across the pulmonary capillaries and the bronchial microvasculature

10 VCAM-1 expression was absent in pulmonary capillaries and unchanged in veins.

11 Pulmonary capillary and pulmonary artery occlusion press

12 trapping of T cells and neutrophils in mouse pulmonary capillaries, and observed neutrophil mobilizat

13 nia, sequestration of neutrophils within the pulmonary capillaries, and release of neutrophils from t

14 ndothelium of the liver and spleen or in the pulmonary capillaries, and was highly dependent on nanop

15 by type II cell hyperplasia, obliteration of pulmonary capillaries, and widespread expression of alph

16 The walls of pulmonary capillaries are extremely thin, and wall stres

17 s and defects in the formation of peripheral pulmonary capillaries as evidenced by significant reduct

18 ment from the carrier b-RBC, probably in the pulmonary capillaries, because lung level of 125I was tw

19 ling pulmonary artery pressure closer to the pulmonary capillary bed and LA pressure closer to the ve

20 emic venous blood to bypass gas exchange and pulmonary capillary bed processing.

21 at allow systemic venous blood to bypass the pulmonary capillary bed through anatomic right-to-left s

22 ion has been proposed to expose parts of the pulmonary capillary bed to high pressure and vascular in

23 eflect the effects of uniform filling of the pulmonary capillary bed.

24 ce or tissue mechanics, we hypothesized that pulmonary capillary blood flow would increase in associa

25 olar-capillary membrane conductance (DM) and pulmonary capillary blood volume (Vc), were sensitive to

26 ociation with HIB, resulting in increases in pulmonary capillary blood volume (VC).

27 We conclude that pulmonary capillary blood volume does not change followi

28 adient for NO between the alveolar space and pulmonary capillary blood, which results in a decrease i

29 ium results in an almost complete absence of pulmonary capillaries, demonstrating the dependence of p

30 capillaries, demonstrating the dependence of pulmonary capillary development on epithelium-derived Ve

31 vasculature, establishing the dependence of pulmonary capillary development on epithelium-derived Ve

32 iffusing capacity in terms of hematocrit and pulmonary capillary diameter.

33 ng that neutrophil margination in uninfected pulmonary capillaries does not require E- and P-selectin

34 e show that repetitive lung injury activates pulmonary capillary endothelial cells (PCECs) and periva

35 We show that PNX stimulates pulmonary capillary endothelial cells (PCECs) to produce

36 antavirus antigens have been demonstrated in pulmonary capillary endothelial cells, but the mechanism

37 lecule 1 (ICAM-1; CD54) was expressed in the pulmonary capillary endothelium and minimally in the end

38 hypothermic pulmonary artery flushing on the pulmonary capillary filtration coefficient (Kfc), and ad

39 isolated, perfused lung model to measure the pulmonary capillary filtration coefficient and hemodynam

40 hyperinflation lung injury as determined by pulmonary capillary filtration coefficient.

41 Pulmonary capillary hemangiomatosis (PCH) is a rare caus

42 factor 2 alpha kinase 4 (EIF2AK4) that cause pulmonary capillary hemangiomatosis and pulmonary veno-o

43 AH and with pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis recruited to the Nat

44 and 16 with pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis were recruited.

45 om analysis due to the subsequent finding of pulmonary capillary hemangiomatosis.

46 iagnosis of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis.

47 escribed in pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis.

48 Pulmonary capillary leak was estimated using radioiodina

49 ssin or norepinephrine limits edema, reduces pulmonary capillary leak, and modulates systemic and pul

50 expression and activity were determined and pulmonary capillary leakage assessed by the Evans blue a

51 remote organ injury as manifested by reduced pulmonary capillary leakage.

52 alk between respiratory epithelial cells and pulmonary capillaries necessary for the formation of the

53 enuded megakaryocyte nuclei were seen in the pulmonary capillaries of mice.

54 Neutrophils in the pulmonary capillaries of rabbits given complement fragme

55 eum, neutrophil emigration across either the pulmonary capillaries or the bronchial microvasculature

56 terized by pulmonary hypertension, increased pulmonary capillary permeability, and hypoxemia.

57 There was a significant increase in pulmonary capillary permeability, wet/dry lung weight ra

58 pathogenic mechanisms of TRALI is increased pulmonary capillary permeability, which results in movem

59 ypothermic modified Euro-Collins solution on pulmonary capillary permeability.

60 compared five literature-based estimates of pulmonary capillary pressure (Ppc) with the correspondin

61 PAOP, mean pulmonary arterial pressure, and pulmonary capillary pressure increased after endotoxin i

62 Oleic acid lung injury increases pulmonary capillary pressure independent of pulmonary ar

63 ure, mean pulmonary arterial pressure, PAOP, pulmonary capillary pressure, and pulmonary arterial and

64 nsive-hyperdynamic circulation; increases in pulmonary capillary pressure, net fluid balance, lung an

65 tial contributor to the constant increase in pulmonary capillary pressure.

66 ining the sequestered neutrophils within the pulmonary capillaries required both L-selectin and CD11/

67 mulate neutrophil transit through individual pulmonary capillary segments to determine the relative e

68 parasitized red blood cells were seen inside pulmonary capillaries, suggesting some sequestration in

69 flow rate can alter the size of the perfused pulmonary capillary surface area.

70 through the alveolar-capillary membrane into pulmonary capillaries, through the plasma, and into eryt

71 d to measure right atrial, pulmonary artery, pulmonary capillary wedge and systemic blood pressures.

72 Pulmonary capillary wedge decreased 37% (P=0.009), cardi

73 e average cardiac index increased 89.5%, and pulmonary capillary wedge decreased 52.2%.

74 05 versus placebo for both) without altering pulmonary capillary wedge or mean arterial pressure, hea

75 s in the right atrium, pulmonary artery, and pulmonary capillary wedge positions.

76 ricular ejection fraction 21+/-1%) who had a pulmonary capillary wedge pressure >/=15 mm Hg and a car

77 Patients with a baseline pulmonary capillary wedge pressure >/=15 mm Hg and a car

78 ) >/=15 mm Hg (right ventricular [RV] DD) or pulmonary capillary wedge pressure >/=18 mm Hg (left ven

79 with systolic blood pressure <100 mm Hg and pulmonary capillary wedge pressure >/=24 mm Hg and depen

80 At rest, 10 patients in MI+DD (29%) had pulmonary capillary wedge pressure >15 (14+/-4 mm Hg), w

81 d units, accurately identified patients with pulmonary capillary wedge pressure >15 mm Hg (area under

82 ropic and intra-aortic balloon pump support, pulmonary capillary wedge pressure >20 mm Hg and serum c

83 esistance > 240 dynes x second x cm(-5), and pulmonary capillary wedge pressure < or = 15 mm Hg.

84 an pulmonary artery pressure >/=25 mm Hg and pulmonary capillary wedge pressure </=15 mm Hg at right

85 ic algorithm for discrimination between mean pulmonary capillary wedge pressure </=15 versus >15 mm H

86 pulmonary arterial pressure >/=25 mm Hg and pulmonary capillary wedge pressure </=15mm Hg).

87 venous crystalloid, furosemide, mannitol (if pulmonary capillary wedge pressure <20 mm Hg), and low-d

88 York Heart Association class II-IV, elevated pulmonary capillary wedge pressure (>/=15 mm Hg at rest

89 During exercise, an abnormal rise in pulmonary capillary wedge pressure (>25 mm Hg) was obser

90 vaptan at 20 and 40 mg significantly reduced pulmonary capillary wedge pressure (-2.6+/-0.7, -5.4+/-0

91 Inhaled nitrite reduced resting pulmonary capillary wedge pressure (-4+/-3 versus -1+/-2

92 of therapy, net reductions in 0-hour trough pulmonary capillary wedge pressure (-4.3 mm Hg; P=0.16),

93 Tolvaptan at all doses significantly reduced pulmonary capillary wedge pressure (-6.4 +/- 4.1 mm Hg,

94 5.2 +/- 2.4 liters/min, p < 0.01), increased pulmonary capillary wedge pressure (17 +/- 7 vs. 14 +/-

95 -5 versus 4+/-1 mm Hg; P=0.0002), and higher pulmonary capillary wedge pressure (17+/-5 versus 9+/-3

96 essure (149 +/- 16 vs. 108 +/- 14 mm Hg) and pulmonary capillary wedge pressure (18 +/- 2 vs. 12 +/-

97 (22+/-8 versus 11+/-4 mm Hg; P=0.0001), and pulmonary capillary wedge pressure (18+/-5 versus 10+/-4

98 essure (29+/-2 to 25+/-2 mm Hg; P<0.05), and pulmonary capillary wedge pressure (25+/-2 to 20+/-2 mm

99 enous pressure (15 vs. 13 mm Hg; p = 0.001), pulmonary capillary wedge pressure (29 vs. 24 mm Hg; p =

100 ues, dipyridamole resulted in an increase in pulmonary capillary wedge pressure (54 +/- 78% vs. 32 +/

101 rimary composite efficacy end point included pulmonary capillary wedge pressure (72 to 96 hours) and

102 nduced significant dose-related decreases in pulmonary capillary wedge pressure (average change -5.9+

103 (CHF, 48+/-12; LVAD, 30+/-5 mm Hg) and mean pulmonary capillary wedge pressure (CHF, 31+/-11; LVAD,

104 - 5 ml/beat per min, p < 0.01) and increased pulmonary capillary wedge pressure (from 25 +/- 2 to 29

105 mm Hg increase; P = 0.022), diastolic PAP - pulmonary capillary wedge pressure (HR, 2.19; 95% CI, 1.

106 However, elevation of the pulmonary capillary wedge pressure (n=8142) had a larger

107 ection fraction (p = 0.02, r = 0.83), higher pulmonary capillary wedge pressure (p = 0.01, r = 0.58)

108 on fraction (p = 0.008, r = 0.88) and higher pulmonary capillary wedge pressure (p = 0.02, r =0.54).

109 reduction in the workload corrected exercise pulmonary capillary wedge pressure (P<0.01).

110 hanges in right atrial pressure (P=0.36) and pulmonary capillary wedge pressure (P=0.53) were not.

111 (2)) was measured by intraarterial catheter, pulmonary capillary wedge pressure (Pcw), continuous car

112 (cardiac index < or =2.5 l/min per m(2) and pulmonary capillary wedge pressure (PCWP) > or =15 mm Hg

113 of right atrial pressure (RAP) >12 mm Hg or pulmonary capillary wedge pressure (PCWP) >15 mm Hg were

114 decreases in creatinine (2.6 to 1.5 mg/dL), pulmonary capillary wedge pressure (PCWP) (32 to 14 mm H

115 d, grouping patients by baseline measures of pulmonary capillary wedge pressure (PCWP) and cardiac in

116 ad as shown by significant increases in both pulmonary capillary wedge pressure (PCWP) and central ve

117 to have a strong positive relationship with pulmonary capillary wedge pressure (PCWP) and left ventr

118 significant relations were observed between pulmonary capillary wedge pressure (PCWP) and sole param

119 s were placed in 11 subjects for measures of pulmonary capillary wedge pressure (PCWP) and SV (thermo

120 Although right atrial pressure (RAP) and pulmonary capillary wedge pressure (PCWP) are correlated

121 In the prospective group, pulmonary capillary wedge pressure (PCWP) derived as: PC

122 ppler echocardiography, BNP measurement, and pulmonary capillary wedge pressure (PCWP) determination.

123 Increases in pulmonary capillary wedge pressure (PCWP) develop in pat

124 lic velocity (E/Ea) has been correlated with pulmonary capillary wedge pressure (PCWP) in a wide vari

125 es (BNP) can serve as noninvasive markers of pulmonary capillary wedge pressure (PCWP) in the setting

126 t of 60 patients had invasive measurement of pulmonary capillary wedge pressure (PCWP) simultaneous w

127 The eoPH and ePVH groups had higher pulmonary capillary wedge pressure (PCWP) than the ePH g

128 Pulmonary capillary wedge pressure (PCWP) was estimated

129 ardiac index, pulmonary artery pressure, and pulmonary capillary wedge pressure (PCWP) were recorded.

130 ft ventricular ejection fraction, 22 +/- 9%; pulmonary capillary wedge pressure (PCWP), 16 +/- 10 mm

131 of renal sympathetic nerve activity (RSNA), pulmonary capillary wedge pressure (PCWP), and mean arte

132 ation was performed in eight males from whom pulmonary capillary wedge pressure (PCWP), central venou

133 entricular filling pressure, as expressed by pulmonary capillary wedge pressure (PCWP), during lower-

134 D, Corvia Medical) was associated with lower pulmonary capillary wedge pressure (PCWP), fewer symptom

135 We measured pulmonary capillary wedge pressure (PCWP), SV, left vent

136 All doses of istaroxime lowered pulmonary capillary wedge pressure (PCWP), the primary e

137 duration had significant relations with mean pulmonary capillary wedge pressure (PCWP).

138 endent association between the reductions in pulmonary capillary wedge pressure (PCWP; 25.4, 24.6, 24

139 and compared them by linear regression with pulmonary capillary wedge pressure (pw).

140 orrelated significantly with changes in mean pulmonary capillary wedge pressure (r=0.63, P<0.001).

141 CS CNP levels correlated with mean pulmonary capillary wedge pressure (r=0.82, P=0.007).

142 ance 24%, pulmonary vascular resistance 25%, pulmonary capillary wedge pressure 33%, and central veno

143 ance, whereas levels of ADMA correlated with pulmonary capillary wedge pressure and both systolic and

144 e, included higher right atrial pressure and pulmonary capillary wedge pressure and lower cardiac ind

145 Pulmonary capillary wedge pressure and LV end-diastolic

146 ventricular (LV) pressure-volume curves from pulmonary capillary wedge pressure and LV end-diastolic

147 Pulmonary capillary wedge pressure and LV end-diastolic

148 age- and sex-related normative responses of pulmonary capillary wedge pressure and mean pulmonary ar

149 on fraction exhibit the largest increases in pulmonary capillary wedge pressure and mean pulmonary ar

150 ressure >25 mmHg in the presence of a normal pulmonary capillary wedge pressure and portal hypertensi

151 Tezosentan also dose-dependently reduced pulmonary capillary wedge pressure and pulmonary and sys

152 te analysis, cardiopulmonary exercise tests, pulmonary capillary wedge pressure and serum sodium were

153 nd-diastolic volume and Starling curves from pulmonary capillary wedge pressure and SV during lower b

154 tal effect on cardiac output, stroke volume, pulmonary capillary wedge pressure and systemic vascular

155 e with shock, pulmonary artery catheter use, pulmonary capillary wedge pressure and the incidence of

156 Higher pulmonary capillary wedge pressure appears to enhance ne

157 lted in a significantly greater reduction in pulmonary capillary wedge pressure at 3, 4, and 8 hours

158 diography, but there was no effect of age on pulmonary capillary wedge pressure at any point througho

159 ction fraction higher than 40%, and a raised pulmonary capillary wedge pressure at rest (>15 mm Hg) o

160 After 9 weeks there were no differences in pulmonary capillary wedge pressure at rest (13+/-4 versu

161 ratio was correlated with directly measured pulmonary capillary wedge pressure at rest (r=0.63, P<0.

162 , 31 (52%) of 60 patients had a reduction in pulmonary capillary wedge pressure at rest, 34 (58%) of

163 2.6-3.8 L.min(-1).m(-2)]; P<0.001) and mean pulmonary capillary wedge pressure decreased (from 15 mm

164 x increased 70.6% by 48 hours after implant, pulmonary capillary wedge pressure decreased 44%, system

165 artery mean pressure decreased 19% (P=0.03), pulmonary capillary wedge pressure decreased 46% (P=0.00

166 peratively, the cardiac index increased 43%, pulmonary capillary wedge pressure decreased 52%, system

167 rom 38.3 +/- 1.6 to 25.9 +/- 1.7 mm Hg; mean pulmonary capillary wedge pressure decreased from 25.1 +

168 Pulmonary capillary wedge pressure decreased from 28.5+/

169 Pulmonary capillary wedge pressure decreased from 28.8+/

170 d pulmonary hypertension (n=1009) and normal pulmonary capillary wedge pressure displayed a consisten

171 The primary end point was the pulmonary capillary wedge pressure during exercise.

172 pressure at rest, 34 (58%) of 59 had a lower pulmonary capillary wedge pressure during exertion, and

173 2 mm Hg) or controls (9+/-2 mm Hg) displayed pulmonary capillary wedge pressure elevation (P=0.03).

174 Exercise elicits greater pulmonary capillary wedge pressure elevation compared wi

175 /Ea) greater than 10 is predictive of a mean pulmonary capillary wedge pressure greater than 15 mm Hg

176 The mean pulmonary capillary wedge pressure in patients with PHTN

177 In healthy subjects, pulmonary capillary wedge pressure increased from 10+/-2

178 Mean pulmonary capillary wedge pressure increased from 9.3 +/

179 l pressure, pulmonary arterial pressure, and pulmonary capillary wedge pressure increased similarly w

180 re paradoxically increase stroke volume when pulmonary capillary wedge pressure is lowered with vasod

181 preserved cardiac index (2.4 liters/min.m2), pulmonary capillary wedge pressure of 16 +/- 9 mm Hg (me

182 monary artery pressure of 40.5+/-11.4 mm Hg, pulmonary capillary wedge pressure of 22.6+/-8.9 mm Hg,

183 ass IV, cardiac index of 1.7 L/min per m(2), pulmonary capillary wedge pressure of 25.6 mm Hg, and le

184 any level of cardiac filling volume was the pulmonary capillary wedge pressure of the seniors lower

185 ion fraction exhibited a steeper increase in pulmonary capillary wedge pressure relative to infused v

186 Older women displayed a steeper increase in pulmonary capillary wedge pressure relative to volume in

187 The mean pulmonary capillary wedge pressure rose from 25+/-14 to

188 (6-17) mm Hg, CVP was 8.5 (6-18) mm Hg, and pulmonary capillary wedge pressure was 18 (14-21) mm Hg.

189 x was 1.39 +/- 0.43 L . min(-)(1) . m(-)(2), pulmonary capillary wedge pressure was 31.5 +/- 5.7 mm H

190 )) was 21.6 +/- 4 mL . kg(-)(1) . min(-)(1), pulmonary capillary wedge pressure was 5.9 +/- 4.6 mm Hg

191 VP and CVP was 0.4 mm Hg and between PVP and pulmonary capillary wedge pressure was 7.5 mm Hg.

192 Pulmonary capillary wedge pressure was correlated with b

193 heart rate, systemic vascular resistance and pulmonary capillary wedge pressure was evident at 3 min

194 Mean exercise pulmonary capillary wedge pressure was lower at 6 months

195 Pulmonary capillary wedge pressure was reduced from a me

196 fraction were similar for the two groups but pulmonary capillary wedge pressure was slightly lower fo

197 After study drug administration, exercise pulmonary capillary wedge pressure was substantially imp

198 y artery catheterization with measurement of pulmonary capillary wedge pressure waveform during 5 dif

199 tly by performing a detailed analysis of the pulmonary capillary wedge pressure waveform obtained by

200 creased and systemic vascular resistance and pulmonary capillary wedge pressure were decreased, as co

201 e highly correlated (r=0.947), while PVP and pulmonary capillary wedge pressure were found to be mode

202 P), mean pulmonary artery pressure (PAP) and pulmonary capillary wedge pressure were obtained by stan

203 ion, HFpEF subjects displayed an increase in pulmonary capillary wedge pressure with exercise from 20

204 TR subjects displayed higher pulmonary capillary wedge pressure with exercise, but th

205 action, augments cardiac output, and reduces pulmonary capillary wedge pressure without causing delet

206 ation of elevated cardiac filling pressures (pulmonary capillary wedge pressure).

207 Pulmonary capillary wedge pressure* decreased to a large

208 ; Fick cardiac output, 11.4+/-3.3 L/min; and pulmonary capillary wedge pressure, 13+/-4 mm Hg.

209 en shown to improve cardiac output, decrease pulmonary capillary wedge pressure, and reduce pulmonary

210 jection fraction and cardiac index, elevated pulmonary capillary wedge pressure, and renal impairment

211 Primary end point was pulmonary capillary wedge pressure, and secondary end po

212 BP, cardiac output, heart rate, pulmonary capillary wedge pressure, and systemic vascula

213 hat this relation may be changed by elevated pulmonary capillary wedge pressure, augmenting right ven

214 iac performance, improving cardiac index and pulmonary capillary wedge pressure, but statistical sign

215 oss the spectrum of systemic blood pressure, pulmonary capillary wedge pressure, cardiac index, and e

216 ffect on heart rate, mean arterial pressure, pulmonary capillary wedge pressure, cardiac index, or sy

217 ted statistically significant differences in pulmonary capillary wedge pressure, cardiac output, pulm

218 Elevated LV end-diastolic or pulmonary capillary wedge pressure, consistent with dias

219 n on echocardiography, ratio of right atrial/pulmonary capillary wedge pressure, hemoglobin) was crea

220 ials in congestive heart failure to decrease pulmonary capillary wedge pressure, improve cardiac outp

221 The pulmonary capillary wedge pressure, lactic acid level, a

222 face area, cardiac index, ejection fraction, pulmonary capillary wedge pressure, left ventricular dim

223 ubgroup, left atrial dilatation, increase of pulmonary capillary wedge pressure, PAP and RAP were mor

224 Pulmonary capillary wedge pressure, pulmonary arterial p

225 ured included cardiac output, stroke volume, pulmonary capillary wedge pressure, systemic and pulmona

226 ted pulmonary vascular resistance and normal pulmonary capillary wedge pressure, we make a weak recom

227 ncrease in estimated trans-septal gradient (=pulmonary capillary wedge pressure-right atrial pressure

228 However, LV transmural pressure (pulmonary capillary wedge pressure-right atrial pressure

229 ering mean arterial pressure, heart rate, or pulmonary capillary wedge pressure.

230 ween diastolic pulmonary artery pressure and pulmonary capillary wedge pressure.

231 ly associated with worse symptoms and higher pulmonary capillary wedge pressure.

232 duce systemic vascular resistance as well as pulmonary capillary wedge pressure.

233 ient, left ventricular systolic pressure and pulmonary capillary wedge pressure.

234 r flow propagation velocities for estimating pulmonary capillary wedge pressure.

235 nadequate LV diastolic filling, despite high pulmonary capillary wedge pressure.

236 e infusion with simultaneous measurements of pulmonary capillary wedge pressure.

237 pulmonary fibrosis, patient age, and varying pulmonary capillary wedge pressure.

238 heir diastolic pulmonary artery pressure and pulmonary capillary wedge pressure.

239 essure: 105 +/- 12 mm Hg to 98 +/- 13 mm Hg; pulmonary capillary wedge pressure: 17 +/- 6 mm Hg to 21

240 ween different echocardiographic indices and pulmonary capillary wedge pressures (PCWP) in normal vol

241 Pulmonary capillary wedge pressures and left ventricular

242 Pulmonary capillary wedge pressures and LV end-diastolic

243 Right atrial and pulmonary capillary wedge pressures increased from 6 +/-

244 on had higher resting pulmonary arterial and pulmonary capillary wedge pressures than the remaining h

245 OMA+D decreased pulmonary arterial and pulmonary capillary wedge pressures to a greater level t

246 arterial, pulmonary artery, right atrial and pulmonary capillary wedge pressures, cardiac index, syst

247 re are further rises in pulmonary artery and pulmonary capillary wedge pressures, suggesting abnormal

248 stration did not change systemic arterial or pulmonary capillary wedge pressures.

249 systemic, right atrial, pulmonary artery, or pulmonary capillary wedge pressures; cardiac index; resp

250 e (non-failing), BNP lowered central venous, pulmonary capillary wedge, diastolic, mean pulmonary art

251 osimendan caused dose-dependent decreases in pulmonary capillary wedge, right atrial, pulmonary arter

252 030 microg per kilogram per minute decreased pulmonary-capillary wedge pressure by 6.0 and 9.6 mm Hg,

253 of a Swan-Ganz catheter, 127 patients with a pulmonary-capillary wedge pressure of 18 mm Hg or higher

254 The cardiac index and pulmonary-capillary wedge pressure were elevated in the

255 arterial pressures, and it had no effect on pulmonary-capillary wedge pressure, right atrial pressur